---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-005427"
form_type: "8-K"
ticker: "ASBP"
cik: "0001847345"
company_name: "Aspire Biopharma Holdings, Inc."
filed_at: "2025-04-18T23:59:59+00:00"
generated_at: "2026-05-23T11:13:35.794060+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aspire Biopharma receives Nasdaq delisting notices for MVLS below $50M and bid price under $1.00

## Summary
- Received two letters on April 16, 2025: MVLS deficiency (below $50M for 30 consecutive days) and bid price deficiency (below $1.00).
- Company has 180 days until October 13, 2025 to regain compliance with MVLS; must achieve at least $50M for 10 consecutive business days.
- Bid Price Rule allows 180-day compliance period; failure may lead to delisting or transfer to Nasdaq Capital Market.
- Company is evaluating potential responses but has not decided on actions; no assurance of regaining compliance.
- Tickers affected: ASBP (common stock) and ASBPW (warrants), both on Nasdaq Global Market.

## SEC filing metadata
- accession: 0001641172-25-005427
- form_type: 8-K
- ticker: ASBP
- cik: 0001847345
- company_name: Aspire Biopharma Holdings, Inc.
- filed_at: 2025-04-18T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847345/000164117225005427/0001641172-25-005427-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847345/000164117225005427/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-005427
- JSON: https://secwatch.observer/filing/0001641172-25-005427.json
- Plain text: https://secwatch.observer/filing/0001641172-25-005427.txt

## Key facts
- Listing & Compliance Notices
  Aspire Biopharma Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1)
  source text: April 16, 2025, Aspire Biopharma Holdings, Inc. (the “Company”), received two letters from the Nasdaq Stock Exchange LLC (“Nasdaq”), each addressing a separate compliance deficiency under the Nasdaq Listing Rules. The first letter notified of the deficiency with regard to Rule 5450(b)(2)(A) (the “MVLS Notice”), which requires a company, whose securities are listed on The Nasdaq Global Market under the “Market Value Standard”, to maintain a minimum Market Value of Listed Securities (an “MVLS”) of $50,000,000. The deficiency was caused by the Company’s MVLS having been below the minimum level fo
  evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000164117225005427/0001641172-25-005427-index.htm
- Listing & Compliance Notices
  Aspire Biopharma Holdings, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5810(c)(3)(C)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 5450(b)(2)(A), 5810(c)(3)(C)
  source text: April 16, 2025, Aspire Biopharma Holdings, Inc. (the “Company”), received two letters from the Nasdaq Stock Exchange LLC (“Nasdaq”), each addressing a separate compliance deficiency under the Nasdaq Listing Rules. The first letter notified of the deficiency with regard to Rule 5450(b)(2)(A) (the “MVLS Notice”), which requires a company, whose securities are listed on The Nasdaq Global Market under the “Market Value Standard”, to maintain a minimum Market Value of Listed Securities (an “MVLS”) of $50,000,000. The deficiency was caused by the Company’s MVLS having been below the minimum level fo
  evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000164117225005427/0001641172-25-005427-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.